In 2018, 662 new cases of mesothelioma were recorded in Australia, with the age of people diagnosed ranging from 22 to 101 years, notes a new report based on Australian Mesothelioma Registry data and released by the Australian Institute of Health and Welfare. The report, Mesothelioma in Australia 2018, also showed that at least 699 people died from mesothelioma during that year, and of those for whom exposure was detected, 65% had possible or probable occupational exposure. From 1982 to 2017, new cases of mesothelioma rose steadily: 135 to 631 cases for males and 22 to 128 cases for females. Read more at: www.aihw.gov.au/reports/cancer/mesothelioma-in-australia-2018.
The product information for direct-acting oral anticoagulants (DOACs) registered in Australia (apixaban, dabigatran etexilate and rivaroxaban) are being updated to include new information on the increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (APS), the TGA has announced. These medications are not recommended in patients with APS, particularly those who are triple positive for lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein I antibodies, the TGA notes. Read more at: www.tga.gov.au/publication-issue/direct-acting-oral-anticoagulants-and-risk-recurrent-thrombotic-events.